Agenus (AGEN) Misses Q2 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Agenus (AGEN) Announces Positive Opinion on Glaxo's (GSK) Malaria Vaccine from EMA
July 24, 2015 6:00 AM EDTAgenus (NASDAQ: AGEN) announced that GlaxoSmithKline (NYSE: GSK) received a positive opinion for its Malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine candidate, named Mosquirix (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision. Agenus adjuvant QS-21 is designed to increase immune response to antigens in vaccines. The positive opinion signals that... More



